Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here's the latest list of major oversold players in this sector, having an RSI near or below 30.

Zai Lab Ltd – ADR (NASDAQ:ZLAB)

• On Jan. 13, Zai Lab highlighted strategic priorities and global pipeline progress at 44th Annual J.P. Morgan Healthcare Conference. “Since our founding, we have intentionally built Zai Lab as a dual-engine company – combining a commercially profitable and scaling China business with a global innovation engine that is now reaching a pivotal inflection point,” said Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “With Zoci now in Phase 3 and multiple global programs advancing behind it, we are entering our next phase with a highly efficient, globally integrated R&D platform, a strong balance sheet, and the capabilities to execute at scale.” The company's stock fell around 10% over the past month and has a 52-week low of $15.96.
• RSI Value: 29.9
• ZLAB Price Action: Shares of Zai Lab fell 1.8% to close at $16.30 on Monday.
• Edge Stock Ratings: 2.22 Momentum score.

Vivos Therapeutics Inc (NASDAQ:VVOS)         

• On Jan. 16, Vivos Therapeutics announced the exercise of warrants generating $4.64 million in gross proceeds. The company's stock fell around 34% over the past month and has a 52-week low of $1.56.
• RSI Value: 29.9
• VVOS Price Action: Shares of Vivos Therapeutics closed at $1.62 on Monday.
• Benzinga Pro’s charting tool helped identify the trend in VVOS stock.

Certara Inc (NASDAQ:CERT)

• On Jan. 8, Keybanc analyst Scott Schoenhaus maintained Certara with an Overweight rating and lowered the price target from $13 to $12. The company's stock fell around 18% over the past five days and has a 52-week low of $8.02.
• RSI Value: 29.9
• CERT Price Action: Shares of Certara fell 5.6% to close at $8.30 on Monday.
• Benzinga Pro’s signals feature notified of a potential breakout in CERT shares.

Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.

Photo via Shutterstock